E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/14/2005 in the Prospect News Biotech Daily.

Merrill reinstates Affymetrix at sell rating

Affymetrix Inc. was reinstated by Merrill Lynch analyst J. Darryl Pardi at a sell rating and $30 price target as Merrill said it forecasts earnings per share to decline 4% to $0.84 in 2006. The stock appears to be priced for a best-case scenario, Merrill said. Shares of the Santa Clara, Calif., maker of scientific instruments were down $1.63, or 3.61%, at $43.58 on volume of 1,296,588 shares versus the three-month running average of 1,017,350 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.